Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus

MLA

Ariel Hammerman, et al. “Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.” The American Journal of Cardiology, vol. 170, May 2022, pp. 128–31. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b8d54a81d6bf480512f7095122c9e80f&authtype=sso&custid=ns315887.

APA

Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, Joseph Azuri, & Ronen Arbel. (2022). Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology, 170, 128–131.

Chicago

Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, Joseph Azuri, and Ronen Arbel. 2022. “Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.” The American Journal of Cardiology 170 (May): 128–31. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b8d54a81d6bf480512f7095122c9e80f&authtype=sso&custid=ns315887.